Neptune Technologies dividend update

Laval, Québec, CANADA – August 11th, 2008 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.V.NTB) announces, in reference to and in payment of its dividend declared on July 17, 2008 to all its common shareholders registered as of July 28, 2008 in the aggregate amount of $9,380.36, the issuance of an aggregate of 9,380,355 notes. Each note has a principal value of $0.001, bears interest from the first anniversary date of their issuance at a rate of ten percent (10%) per annum and is due two years after the date hereof. These notes are redeemable by the obligor at any time, by advance payment, either in cash or in kind, including in equity securities of the obligor of such notes.

About Neptune
Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical, medical food and pharmaceutical applications. Through clinical research, Neptune is showing the clinical benefits of its products in various therapeutic indications with a focus on cardiovascular and cognitive health. The Company has been successful in patenting and protecting its intellectual property, and will continue to protect its innovations. Neptune has already obtained regulatory approvals allowing commercialization of its products and has filed for and is expecting additional approvals.

Neptune continues to strongly support its strategic development plan to form partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. Neptune signed agreements with Nestlé and Yoplait, worldwide leading food manufacturers, and paved its entrance into the global functional food market. According to its business strategy, negotiations with pharmaceutical companies with the objective of entering the pharmaceutical market by licensing rights are ongoing.